Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 9/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12502513 | 0.80 | JAK2 (0.46) | PRMT5WDR77GSK3AGSK3BCA1 | |
| SCHEMBL30379604 | 0.80 | PRMT5 (0.42) | PRMT5WDR77GSK3AGSK3BCA1 | |
| SCHEMBL1519972 | 0.80 | PRMT5 (0.42) | PRMT5WDR77GSK3AGSK3BCA1 | |
| SCHEMBL15799446 | 0.79 | PRMT5 (0.41) | PRMT5WDR77GSK3AGSK3BCA1 | |
| SCHEMBL15799090 | 0.79 | LPL (0.44) | PRMT5WDR77GSK3AGSK3BCA1 | |
| SCHEMBL31725403 | 0.77 | PRKAG1 (0.48) | PRMT5WDR77GSK3AGSK3BLPL | |
| SCHEMBL5475399 | 0.77 | PRMT5 (0.47) | PRMT5WDR77GSK3AGSK3BCA1 | |
| SCHEMBL17205845 | 0.76 | PRMT5 (0.39) | PRMT5WDR77GSK3AGSK3BCA1 | |
| SCHEMBL15288091 | 0.76 | PRMT5 (0.39) | PRMT5WDR77GSK3AGSK3BCA1 | |
| SCHEMBL759272 | 0.74 | ALDH1A1 (0.50) | PRMT5WDR77CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215753-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| US-20180215753-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| US-10023572-B2 | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180148444-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-05-31 | — | — | US | disclosed |
| US-20180148444-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-05-31 | — | — | US | disclosed |
| US-9828372-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828372-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170260179-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2017-09-14 | — | — | US | disclosed |
| US-20170260179-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2017-09-14 | — | — | US | disclosed |
| US-9738638-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738638-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| US-9475807-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475807-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160090380-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-31 | — | — | US | disclosed |
| US-20160090380-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-31 | — | — | US | disclosed |
| US-20160075701-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148444-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | PRMT5 1777/4885WDR77 1129/4885GSK3A 13/4885 |
| US-20180215753-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | PRMT5 1635/4885WDR77 1226/4885GSK3A 14/4885 |
| US-20160075701-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | PRMT5 1635/4885WDR77 1226/4885GSK3A 14/4885 |
| US-20160090380-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | PRMT5 1777/4885WDR77 1129/4885GSK3A 13/4885 |
| US-10023572-B2 | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | PRMT5 1777/4885WDR77 1129/4885GSK3A 13/4885 |
| US-20170260179-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | PRMT5 1635/4885WDR77 1226/4885GSK3A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.